Lyka Labs Limited (LYKALABS) Fair Value & Analysis
Healthcare · IN · Market cap ₹2.6B
Fair value as of: Aug 13, 2026
From 1 valuation models · updated 4 days ago
Share price −3.0% over the past month.
Below-average quality, and screening another 77% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (₹23.69). The favourable scenario is already priced in.
- Weak quality (24/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range (₹11.85 to ₹23.69) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range ₹39.05 – ₹254.30 · fair‑value band ₹11.85 – ₹23.69 · the ₹68.03 price screens above the ₹15.88 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Lyka Labs Limited (LYKALABS) currently trades at ₹68.03, while our model-based Fair Value estimate is ₹15.88, implying the stock looks roughly 76.7% overvalued today. The Quality Score stands at 24/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Lyka Labs Limited generated revenue of ₹1.3B at a net margin of -0.5%. Revenue declined 9.1% year over year. It earns a return on equity of 2.5%. Net debt stands at ₹475M. Fundamentals as of Aug 13, 2026
Our scenario range runs from ₹11.85 (bear case) to ₹23.69 (bull case); at ₹68.03, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 44% below its 52-week high and 54% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -47% fair-value upside, at -77%, LYKALABS screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when LYKALABS reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 26 · Market factors (momentum, volatility) 39
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Lyka Labs Limited, a pharmaceutical company, develops, manufactures, and markets pharmaceutical formulations and active pharmaceutical ingredients in India.
Full company description
Lyka Labs Limited, a pharmaceutical company, develops, manufactures, and markets pharmaceutical formulations and active pharmaceutical ingredients in India. The company manufactures and sells various formulations, including emollient, topical steroid, antifungal agent, topical anti-bacterial, acne management, dermatological formulation, pain killer, anti-aging, cleansing lotion, hair care, anti-dandruff shampoo, sunscreen, anti-acne, cosmeceutical, anti-oxidant tablets and combination, proton pump inhibitor, nutraceuticals, anti-malarial, anti-bacterial, corticosteroid hormones, cephalosporin, dry powder injection, anti-fungal and bacterial, bone resorption inhibitor, anti-oxidant/liver disease, antibiotic, and lyophilized products. It also offers technical data, such as molecule stability testing data, impurity profile, and BA/BE clinical study data. The company offers its products in various forms, including injections, creams, ointments, foams, gels, and lotions. It also exports its products. The company was incorporated in 1976 and is based in Mumbai, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Lyka Labs Limited reported revenue of ₹1.3B in FY2026 versus ₹1.8B in FY2022, a compound −8.5%/yr. Reported net income was −₹100M in FY2026.
LYKALABS screens 77% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Peer Group
Biotechnology · 599 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $525.73 | $278.78 | -47% |
| Regeneron Pharmaceuticals, Inc REGN | $797.99 | $594.40 | -26% |
| Samsung Biologics Co 207940 | 1,549,000 KRW | 1,055,793 KRW | -32% |
| Celltrion, Inc 068270 | 202,000 KRW | 74,519 KRW | -63% |
| WuXi Biologics (Cayman) Inc 2269 | HK$45.70 | HK$30.58 | -33% |
| Innovent Biologics, Inc 1801 | HK$95.55 | HK$19.68 | -79% |
| Genmab A/S GMAB | kr 2,037 | kr 250.07 | -88% |
| Sino Biopharmaceutical Limited 1177 | HK$4.87 | HK$3.37 | -31% |
| RemeGen Co 688331 | ¥131.87 | ¥23.19 | -82% |
| ALTEOGEN Inc 196170 | 314,000 KRW | 39,476 KRW | -87% |
Compare Lyka Labs Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Lyka Labs Limited (LYKALABS) overvalued or undervalued?
What is the fair value of LYKALABS?
What is the quality score of LYKALABS?
What is the revenue of Lyka Labs Limited (LYKALABS)?
What is the net profit margin of LYKALABS?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Lyka Labs Limited and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.